Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

OC-018 Continuing undue risks in UK prescribing of non-steroidal anti-inflammatory drugs

(2016) M Leighton et al.   GUT

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

(2012) Xavier Hébuterne et al.   GUT

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

(2012) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

(2012) Geert DʼHaens et al.   INFLAMMATORY BOWEL DISEASES

Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study

(2011) M. Chaparro et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

(2011) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease

(2011) Laurent Peyrin-Biroulet et al.   Journal of Crohns & Colitis

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents

(2010) Stephen B. Hanauer et al.   INFLAMMATORY BOWEL DISEASES

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

(2010) Gert Van Assche et al.   Journal of Crohns & Colitis

The expanding role of biologic therapy for IBD

(2010) Stephen B. Hanauer   Nature Reviews Gastroenterology & Hepatology

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

(2010) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Predicting the response to infliximab from trough serum levels

(2009) P. Rutgeerts et al.   GUT

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease

(2009) Andrea Cassinotti et al.   INFLAMMATORY BOWEL DISEASES